GRC-101
Rare Focal Epilepsy (e.g., CDKL5 Deficiency Disorder)
Phase 2Active, enrolling
Key Facts
Indication
Rare Focal Epilepsy (e.g., CDKL5 Deficiency Disorder)
Phase
Phase 2
Status
Active, enrolling
Company
About Grace Therapeutics
Grace Therapeutics is a public, clinical-stage biotech company focused on discovering and developing novel therapeutics for rare neurological and neurodevelopmental disorders. Its core strategy is built on a proprietary platform targeting specific neuronal ion channels to address hyperexcitability disorders, with lead programs in rare focal epilepsies and treatment-resistant seizures. The company is actively enrolling patients in Phase 2 and Phase 1/2 trials, positioning itself in a high-need, growing segment of the neurology market. Founded in 2019, Grace seeks to build a sustainable R&D engine to advance its pipeline and address significant unmet medical needs.
View full company profile